Financial Summary (All financials)
| In millions, except per share items | Jan-01-23 | Jan-02-22 | Jan-03-21 | Dec-29-19 | Dec-30-18 | Dec-31-17 | Jan-01-17 | Jan-03-16 |
| Revenues | 3,311.8 | 3,827.8 | 2,663.2 | 2,883.7 | 2,778.0 | 2,257.0 | 2,115.5 | 2,104.8 |
| Revenue growth | -13.5% | 43.7% | -7.6% | 3.8% | 23.1% | 6.7% | 0.5% | 1.7% |
| Cost of goods sold | 1,322.0 | 1,393.8 | 925.5 | 1,487.6 | 1,437.9 | 1,003.6 | 1,100.5 | 1,140.6 |
| Gross profit | 1,989.8 | 2,434.0 | 1,737.8 | 1,396.1 | 1,340.1 | 1,253.4 | 1,015.0 | 964.2 |
| Gross margin | 60.1% | 63.6% | 65.3% | 48.4% | 48.2% | 55.5% | 48.0% | 45.8% |
| Selling, general and administrative | 1,025.5 | 975.2 | 716.5 | 815.3 | 811.9 | 626.0 | 590.5 | 587.2 |
| Research and development | 221.6 | 200.3 | 146.4 | 189.3 | 194.0 | 139.5 | 124.2 | 112.5 |
| EBITA | 1,099.7 | 1,529.4 | 1,035.9 | 555.7 | 470.1 | 561.6 | 371.8 | 341.0 |
| EBITA margin | 33.2% | 40.0% | 38.9% | 19.3% | 16.9% | 24.9% | 17.6% | 16.2% |
| Amortization of intangibles | 370.6 | 256.6 | 161.0 | 164.3 | 135.9 | 73.7 | 71.5 | 76.6 |
| EBIT | 729.1 | 1,272.8 | 874.9 | 391.4 | 334.2 | 487.9 | 300.3 | 264.4 |
| EBIT margin | 22.0% | 33.3% | 32.8% | 13.6% | 12.0% | 21.6% | 14.2% | 12.6% |
| Pre-tax income | 651.8 | 1,203.6 | 800.1 | 237.1 | 257.7 | 296.7 | 244.1 | 208.8 |
| Income taxes | 139.2 | 314.1 | 169.5 | 9.4 | 20.2 | 139.8 | 28.4 | 20.0 |
| Tax rate | 21.3% | 26.1% | 21.2% | 4.0% | 7.8% | 47.1% | 11.6% | 9.6% |
| Earnings from continuing ops | 512.7 | 889.4 | 630.6 | 227.8 | 237.5 | 156.9 | 215.7 | 188.8 |
| Earnings from discontinued ops | 0.0 | 0.0 | | | | | | |
| Net income | 569.2 | 943.2 | 727.9 | 227.6 | 237.9 | 292.6 | 234.3 | 212.4 |
| Net margin | 17.2% | 24.6% | 27.3% | 7.9% | 8.6% | 13.0% | 11.1% | 10.1% |
| |
| Diluted EPS | $4.06 | $7.62 | $5.63 | $2.04 | $2.13 | $1.42 | $1.96 | $1.67 |
| Shares outstanding (diluted) | 126.4 | 116.7 | 112.1 | 111.5 | 111.5 | 110.9 | 110.3 | 113.3 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|